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Abstract
Background:  Whey protein is a potential source of bioactive peptides. Based on findings from in vitro
experiments indicating a novel whey derived peptide (NOP-47) increased endothelial nitric oxide synthesis, we
tested its effects on vascular function in humans.
Methods: A randomized, placebo-controlled, crossover study design was used. Healthy men (n = 10) and women
(n = 10) (25 ± 5 y, BMI = 24.3 ± 2.3 kg/m2) participated in two vascular testing days each preceded by 2 wk of
supplementation with a single dose of 5 g/day of a novel whey-derived peptide (NOP-47) or placebo. There was
a 2 wk washout period between trials. After 2 wk of supplementation, vascular function in the forearm and
circulating oxidative stress and inflammatory related biomarkers were measured serially for 2 h after ingestion of
5 g of NOP-47 or placebo. Macrovascular and microvascular function were assessed using brachial artery flow
mediated dilation (FMD) and venous occlusion strain gauge plethysmography.
Results: Baseline peak FMD was not different for Placebo (7.7%) and NOP-47 (7.8%). Placebo had no effect on
FMD at 30, 60, and 90 min post-ingestion (7.5%, 7.2%, and 7.6%, respectively) whereas NOP-47 significantly
improved FMD responses at these respective postprandial time points compared to baseline (8.9%, 9.9%, and
9.0%; P < 0.0001 for time × trial interaction). Baseline reactive hyperemia forearm blood flow was not different
for placebo (27.2 ± 7.2%/min) and NOP-47 (27.3 ± 7.6%/min). Hyperemia blood flow measured 120 min post-
ingestion (27.2 ± 7.8%/min) was unaffected by placebo whereas NOP-47 significantly increased hyperemia
compared to baseline (29.9 ± 7.8%/min; P = 0.008 for time × trial interaction). Plasma myeloperoxidase was
increased transiently by both NOP-47 and placebo, but there were no changes in markers inflammation. Plasma
total nitrites/nitrates significantly decreased over the 2 hr post-ingestion period and were lower at 120 min after
placebo (-25%) compared to NOP-47 (-18%).
Conclusion:  These findings indicate that supplementation with a novel whey-derived peptide in healthy
individuals improves vascular function.
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Background
The vascular endothelium is a single cell layer lining the
lumen of blood vessels that substantially impacts vascular
health and disease risk by regulating vasoconstriction and
vasodilation, blood pressure, blood clotting, angiogen-
esis, inflammation, and passage of materials between the
circulating blood and the interior components of the ves-
sel wall. An important paracrine factor involved in vascu-
lar homoeostasis is endothelium-derived nitric oxide
(NO·), which is a potent vasodilator that also inhibits
platelet aggregation, inflammatory cell adhesion to the
vessel wall, and smooth muscle cell proliferation [1].
Impaired NO· signaling and endothelial dysfunction
have been implicated in metabolic syndrome [2] and car-
diovascular disease [3]. Therefore, interventions that tar-
get NO· and vascular function are relevant for disease
prevention.
Numerous therapies targeting the vascular endothelium
have been proposed [4]. Nutritional strategies have
focused on antioxidants (e.g., vitamin E, vitamin C,
polyphenols, etc.) because oxidative stress contributes to
endothelial dysfunction. Antioxidant supplementation
mitigates postprandial endothelial dysfunction associated
with high carbohydrate and high fat meals [5]. Oral sup-
plementation [6] and intra-arterial administration [7] of
L-arginine, the rate limiting amino acid for endothelial
NO· synthesis [8], restored impaired endothelial func-
tion in older individuals and in response to a high fat
meal [9], but not in younger adults with normal endothe-
lial function [10].
Bioactive peptides derived from food, especially milk pro-
teins, have been shown to exert a wide range of biological
actions including decreased blood pressure [11,12] and
improved endothelial function[13]. Milk is a rich source
of angiotensin-converting enzyme (ACE) inhibitory pep-
tides [14]. ACE inhibition prevents the conversion of
angiotensin I to angiotensin II, a potent vasoconstrictor.
Several clinical studies have shown improvement in
endothelial function in patients prescribed ACE inhibitors
[4], which could be the result of pleiotropic effects of ACE
inhibitors on the vascular endothelium [15].
A search for isolates from whey protein hydrolysates that
could increase NO production was carried out by Glanbia
Nutritionals. A nitric oxide peptide (NOP-47) was identi-
fied that was shown to increase NO synthesis in vitro as
determined by the analysis of NO· metabolites in human
pulmonary artery endothelial cells (HPAE-26) (data pro-
vided by Glanbia Nutritionals). To extend upon these
findings, we conducted a randomized, double-blind,
cross-over trial to determine if NOP-47 affected vascular
physiology in healthy human volunteers. We hypothe-
sized that a single dose of NOP-47 would enhance vascu-
lar function as measured by flow-mediated dilation
(FMD) of the brachial artery using high-frequency ultra-
sound [16] and reactive hyperemia forearm blood flow
assessed by venous occlusion plethysmography [17].
Forearm FMD measures dilation in a conduit artery and is
considered an index of NO· bioavailability [18] that is
also correlated with coronary artery endothelial function
[19] and cardiovascular disease risk and mortality [20].
Reactive hyperemia venous occlusion plethysmography
measures vasodilation in the resistance vessels, and is not
appreciably affected by NO· in human forearms [21]. A
secondary objective was to characterize the effects of
NOP-47 on circulating markers of antioxidant capacity,
oxidative stress, and inflammation since these factors
have been demonstrated to influence vascular function
though various biologic mechanisms.
Methods
Study design
This study was approved by the Institutional Review
Board for use of human subjects in research at the Univer-
sity of Connecticut. All subjects provided written
informed consent after having the risks of the study care-
fully explained to them. A randomized, placebo-control-
led, crossover study design with a washout period was
conducted. Subjects participated in two vascular testing
days with each preceded by 2 wk of daily supplementation
with either a whey-derived peptide (NOP-47) or placebo.
The order of supplementation was balanced. Following
the completion of the first 2 wk supplementation period
and first day of vascular testing, participants underwent a
minimum 1 wk washout period after which they started
the second 2 wk supplementation period consuming the
alternative supplement. Each subject reported to the lab
for four separate visits (Figure 1, top). In order to elimi-
nate confounding influences on the experimental varia-
bles subjects were instructed to fast for 12 h, avoid
alcohol, caffeine, and exercise for 24 h, and to consume 1
L of water the night before the visit and 480 mL the morn-
ing of the visit to ensure adequately hydration.
Subjects
Healthy volunteers (n = 20) between 21–39 y were stud-
ied (Table 1). Exclusion criteria for subjects included overt
chronic diseases as determined by medical history ques-
tionnaire, hypertension, smoking, use of vasoactive med-
ications or supplements, or weight change greater than 2.3
kg in the past 3 mo. Women were screened to determine
menstrual history and were excluded if hormonal contra-
ceptive use was initiated or changed within the past 3 mo.
Supplementation protocol
The active supplement was a proprietary peptide isolated
from a whey protein hydrolysate (NOP-47, Glanbia
Nutritionals, Twin Falls, ID) (Table 2). A daily dose of 5 gNutrition Journal 2009, 8:34 http://www.nutritionj.com/content/8/1/34
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was pre-measured and placed in individual packets with
artificial sweetener. The placebo was identical except the
packets contained only artificial sweetener (aspartame
and acesulfame potassium). Subjects were provided a 2
wk supply and instructed to consume one packet per day
mixed in 300 mL water. Compliance was 100% as
assessed by written documentation in log books and veri-
fied by study personnel. On the morning of vascular test-
ing, subjects consumed one packet containing 5 g of NOP-
47 or placebo mixed in water in the presence of an inves-
tigator not directly involved in vascular data collection
nor analysis at the completion of the study. Subjects
ingested the beverage within 3 min, after which a timer
was started for the 2 h postprandial testing protocol. A
questionnaire to address subjective symptoms and side
effects associated with each supplement was administered
at the end of the study.
Testing protocol
Upon arrival to the laboratory, participants provided a
urine sample and hydration state was confirmed by meas-
urement of urine specific gravity (USG) with a handheld
refractometer. A USG < 1.020 indicated euhydration. If
USG was > 1.020, then participants were instructed to
Study timeline (A) and vascular testing protocol (B) Figure 1
Study timeline (A) and vascular testing protocol (B). FMD = flow mediated dilation; R-FBF = resting forearm blood 
flow; RH-FBF = reactive hyperemia forearm blood flow.
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drink water until their USG was < 1.020. Body mass was
measured to the nearest 0.1 kg on a calibrated digital
scale.
Visits 1 and 3 consisted of anthropometric measurements,
detailed instructions on filling out dietary records, distri-
bution of supplements, and a single venous blood draw
obtained in a supine position. Visits 2 and 4 occurred on
two occasions at the same time of the day after 2 wk sup-
plementation with NOP-47 or placebo. A flexible catheter
was inserted into a left forearm vein and after a 15 min
supine stabilization period, blood samples were collected
from a 3-way stopcock connected to the end of the cathe-
ter for fasting baseline and subsequent postprandial bio-
chemistry measurements. Next fasting measurements of
FMD and forearm blood flow (FBF) (described below)
were determined. Fifteen minutes of recovery were
allowed between FMD and FBF measurements before
ingestion of the test beverage. Following these baseline
measurements, subjects consumed a single 5 g dose of
either NOP-47 or placebo mixed in 300 mL of water and
with artificial sweetener. Post-ingestion FMD and FBF
measurements were made intermittently (Figure 1, bot-
tom). Blood samples were obtained at 15, 30, 45, 60, 90,
and 120 min post-ingestion. Subjects remained supine in
a comfortable position for the entire duration of the test.
To ensure standardization between testing trials subjects
were instructed to maintain their current level of physical
activity during the study period and to replicate their die-
tary intake from previously recorded diet records the day
prior to each vascular testing visit. Women were assessed
during the same phase of their individual menstrual cycle
as to account for any changes in vascular function [22] or
blood markers due to menstrual phase.
Flow mediated dilation
FMD was assessed using standardized procedures for per-
forming high-frequency ultrasonographic imaging before
(PRE) and at 30, 60, and 90 min after ingestion of the test
beverage. The technique provokes the release of NO·,
resulting in vasodilation that can be quantitated as an
index of vasomotor function [16]. All tests were per-
formed in a quiet, temperature-controlled room after a 10
min period in a supine position. A blood pressure cuff was
placed on the upper right arm for occlusion. ECG leads
were attached to monitor heart rate throughout the proce-
dure. The brachial artery was imaged above the antecu-
bital crease, and the transducer was placed to image the
brachial artery in a longitudinal axis with clear visualiza-
tion of the anterior and posterior vessel walls. When a
clear image of the anterior and posterior walls of the artery
was obtained, the transducer was held by a stereotactic
clamp and the position held constant for the duration of
the data collection. After optimization of the image, base-
line brachial artery diameter was recorded for 30 heart
beats. A mark was made on the arm where the image was
collected. The cuff was inflated to 200 mm Hg for 5 min
using a rapid cuff inflator (Hokanson E20, Bellevue, WA,
USA) to occlude the brachial artery, and then released.
Arterial diameter was then assessed continuously for 300
heart beats after occlusion[16]. Images of the brachial
artery were obtained using an Acuson 13.0-MHz linear
array transducer and an Aspen cardiac ultrasound system
(Acuson Corp, Elmwood Park, NJ). Anatomical measure-
ments were made to ensure placement of the transducer in
the same location on the arm during the second visit.
Image analysis was performed using MIA software (Medi-
cal Imaging Applications, Iowa City, IA, USA). For base-
line, the average diameter taken from 30 frames was used.
Three hundred frames were recorded from the postocclu-
sion period. Peak postocclusion diameter was calculated
by averaging the vessel diameter 5 frames immediately
before the observed peak diameter and the 5 frames
immediately after the same mark. Brachial artery FMD
Table 1: Subject characteristics.
Age, yr 24.8 ± 4.5
Sex (M/F) 10/10
Height, cm 169.5 ± 9.4
Weight, kg 69.8 ± 9.1
BMI, kg·m2 24.3 ± 2.3
SBP, mmHg 110 ± 6
DBP, mmHg 68 ± 5
HR, bpm 57 ± 9
Waist Circumference, cm 77.8 ± 5.6
Values are means ± SD. BMI, body mass index; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; HR, heart rate.
Table 2: Amino acid composition of the whey peptide (NOP-47).
Variables NOP-47
Tryptophan 1.33
Cystine 0.52
Methionine 5.05
Aspartic acid 5.46
Threonine 10.74
Serine 4.29
Glutamic acid 8.21
Proline 2.30
Glycine 1.18
Alanine 6.86
Valine 7.31
Isoleucine 5.69
Leucine 22.40
Tyrosine 2.31
Phenylalanine 4.41
Lysine 5.79
Histidine 1.70
Arginine 1.35
Values are g/100 g powder.
Five grams of powder was mixed with artificial sweetener in 300 mL 
water.Nutrition Journal 2009, 8:34 http://www.nutritionj.com/content/8/1/34
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was calculated and expressed as a percentage of the base-
line diameter [23]. All vascular measurements and analy-
sis were performed by the same person. Using the same
investigative team, coefficients of variation for arterial
diameter on repeat scans with repositioning on a group of
men and women (N = 10) in our laboratory were 2.2% for
measurements made the same day, and 2.2% for measure-
ments made on two consecutive days.
Strain gauge plethysmography
Forearm blood flow was measured from the same arm as
FMD using venous occlusion strain gauge plethysmogra-
phy. A calibrated indium-gallium filled silastic strain
gauge, encircled around the largest diameter of the right
forearm, was connected to a plethysmograph (EC6,
Hokanson, Inc., Bellevue, WA, USA). The increase in fore-
arm volume was measured after blocking the venous
efflux by an upper arm cuff inflated to 50 mmHg by a
rapid cuff inflator (Hokanson E20, Bellevue, WA, USA)
for 7 sec during each 15 sec cycle to determine resting fore-
arm blood flow (R-FBF). This measurement was per-
formed at rest (PRE) and in between the FMD protocol at
20, 50, 80, and 110 min after ingestion of the test bever-
age. The hand circulation was excluded by a wrist cuff
inflated to 220 mmHg for 1 min before and during each
flow evaluation. The forearm blood flow was estimated
using specialized software (Noninvasive Vascular Pro-
gram 3 (NIVP3), Hokanson, Bellevue, WA, USA) which
calculated the slope from the change in forearm volume
over time and determined blood flow as percent volume
change per minute (%/min). Four plethysmographic
measurements were averaged to obtain values for R-FBF.
To determine reactive hyperemia induced forearm blood
flow (RH-FBF), a blood pressure cuff on the upper right
arm was inflated to a pressure of 200 mmHg for 5 min.
FBF was determined as described above upon release of
the occlusion. This measurement was performed at rest
(PRE) and 120 min after ingestion of the test beverage.
Blood collection and biochemical analyses
All blood samples were obtained from the left arm vein
while participants rested quietly in the supine position.
Whole blood was collected into tubes with no preserva-
tive or lithium heparin and centrifuged (1500 × g, 15 min,
4°C). Serum/plasma was transferred into storage tubes,
snap frozen in liquid nitrogen, and stored at -80°C for
future analysis. Samples for each asasy were analyzed in
duplicate. Myeloperoxidase was measured from lithium
heparin plasma by high-sensitivity sandwich ELISA (Car-
dioMPO, Prognostix, Cleveland, OH) (CV = 5.9%).
Serum glucose concentrations were analyzed using a YSI
glucose/lactate analyzer (YSI 2300 STAT, Yellow Springs,
OH). Total nitrite/nitrate (NO2
-/NO3
-) was measured as
an estimate of NO· production using a colorimetric kit
(Cayman Chemical, Ann Arbor, MI, USA) in accordance
with the manufacturer's instructions (CV = 8.0%). Serum
samples were filtered using 10 kDa molecular weight cut-
off filters prior to analysis to reduce background absorb-
ance. Plasma C-reactive protein (CRP) was determined on
an IMMULITE Automated Analyzer using the commer-
cially available immulite chemiluminescent enzyme
immunometric assay (Immulite®, Diagnostic Products
Corp., Los Angeles, CA, USA).
Total plasma antioxidant status was determined using the
ferritin-reducing ability of plasma (FRAP) assay as previ-
ously described [24,25]. Briefly, diluted plasma (1:4) was
mixed on a 96 well plate with 300 μl of freshly prepared
and pre-warmed (37°C) FRAP reagent [50 ml of sodium
acetate buffer (300 mmol/L), 5 ml of TPTZ reagent pre-
pared in 40 mmol/L HCl, and 5 ml of FeCl3 (20 mmol/
L)]. Following incubation (15 min, 37°C), samples were
read at 593 nm on a microplate reader (SpectraMax M2,
Molecular Devices Corporation, Sunnyvale, California,
USA) and FRAP concentrations were calculated using
trolox standards that were prepared in parallel (CV =
4.3%).
Plasma malondialdehyde (MDA) was measured by
HPLC-FL as described previously [26] with minor modifi-
cations. In brief, 200 uL of plasma was mixed with 150 uL
of 5% (w/v) TCA. After centrifugation (4,000 × g, 10 min,
4°C), the supernatant was thoroughly mixed with 50 μL
of 0.6% (w/v) thiobarbituric acid. The sample was incu-
bated (1 h, 100°C), then rapidly chilled in an ice bath,
followed by the addition of 225 μL methanol and 25 μL 1
N NaOH. The supernatant was collected following centrif-
ugation (16,000 × g, 4°C, 10 min) and subsequently
injected (20 μl) on the HPLC system (Beckman Coulter;
Fullerton, CA). The sample was separated on a C18 separa-
tion column (250 × 4.6 mm i.d.; 5 μm; Phenomenex; Tor-
rance, CA) under isocratic (0.9 ml/min) conditions using
60:40 methanol and 50 mM phosphate buffer (pH 5.5) as
the mobile phase. MDA was detected using excitation and
emission settings of 532 nm and 553 nm, respectively,
and was quantified against MDA standards that were pre-
pared in parallel from 1,1,3,3-tetramethoxypropane.
Serum cytokines and chemokines [tumor necrosis factor-
alpha (TNFα), interleukin-6 (IL-6), interleukin-8 (IL-8),
monocyte chemoattractant protein-1 (MCP-1), vascular
endothelial growth factor (VEGF), soluble E-selectin (sE-
Selectin), soluble vascular cell adhesion molecule-1
(sVCAM-1), and soluble intracellular adhesion molecule-
1 (sICAM-1)] were measured using xMAP® technology on
a Luminex® IS 200 system with antibodies to these ana-
lytes from LINCO Research (St. Charles, MO)[27]. Assays
were completed according to manufacturer's instructions.
Statistical analyses
Forearm FMD data was analyzed with a 2 × 4 ANOVA with
supplement trial (NOP-47 vs Placebo) and time (pre, 30,Nutrition Journal 2009, 8:34 http://www.nutritionj.com/content/8/1/34
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60, and 90 min) as within effects. Sex was also included as
an effect, but not found to be statistically significant and
thus men and women were combined in all analyses. Sig-
nificant main or interaction effects were further analyzed
using a Fishers LSD post hoc test. Relationships among
selected variables were examined using Pearson's product-
moment correlation coefficient. The α-level for signifi-
cance was set at 0.05.
Results
Body mass remained stable over the course of the study
(mean ± SD: 70.01 ± 9.27 kg versus 69.59 ± 8.85 kg for
visits 1 and 4, respectively). There were also no significant
changes in systolic or diastolic blood pressure after 2 wk
of supplementation with NOP-47 and placebo. There
were no adverse responses reported by subjects during
either trial. All but one subject correctly identified which
supplement contained NOP-47.
Vascular function
Pre-occlusion diameters were not significantly different
before ingestion of the NOP-47 (3.91 mm) and placebo
(3.90 mm) and remained remarkably stable over time
during both trials (range 3.89 to 3.91 mm) indicating
maintenance in vascular tone over the postprandial
period as well as a high degree of reproducibility in probe
placement and measurement of the artery. Peak FMD
(mean; 95% CI) significantly increased at 30 (8.87; 7.28–
10.46%), 60 (9.94; 7.94–11.94%), and 90 (9.02; 7.41–
10.63%) min post-ingestion in the NOP-47 trial which
were significantly higher than corresponding placebo
time points at 30 (7.52; 5.90–9.07%), 60 (7.21; 5.76–
8.65%), and 90 (7.61; 5.91–9.31%) min (P < 0.0001 for
time × trial interaction) (Figure 2, top). Individual
responses revealed that 15 out of 20 subjects had greater
peak FMD at 60 min (Figure 2, bottom) and 90 min post-
NOP-47 ingestion compared to these same time points
following ingestion of placebo.
Reactive hyperemia forearm blood flow was assessed in
response to 5 min of cuff occlusion by venous occlusion
plethysmography before and 120 min after supplement
ingestion. Maximal hyperemic blood flow was similar
after 2 weeks of supplementation with NOP-47 (27.6 ±
7.6%/min) and placebo (27.6 ± 7.2%/min). The response
to acute ingestion showed a significant increase at 120
min for NOP-47 (29.9 ± 7.5; 95% CI = 26.25–33.58%/
min) and no change for placebo (27.5 ± 7.8; 95% CI =
23.51–30.84%/min) (P = 0.008 for time × trial interac-
tion) (Figure 3). Resting forearm blood flow was also
assessed before supplement ingestion and 20, 50, 80, and
110 min post-ingestion. Compared to hyperemic blood
flow, resting blood flow values were considerably smaller
in magnitude and only showed a significant main time
effect (P = 0.002) as reflected by a significant increase at
110 min compared to pre-ingestion.
Hematological responses
Hematoligical responses are presented in Table 3. Serum
glucose was unaffected by 2 wk of supplementation or
acute ingestion. Plasma nitrites/nitrates (NOx) decreased
significantly over time (P < 0.001; Figure 4) and specific
post-hoc effects were observed at 90 and 120 min com-
pared to pre-ingestion. There was a greater decline in sub-
jects consuming the placebo at the 120 min time point (P
= 0.03). There was a significant time effect for serum FRAP
(P = 0.001) with values at 30 min higher than baseline.
Fasting plasma MPO was not affected by 2 wk of supple-
mentation. However, there was a significant main time
effect in response to acute supplementation ingestion
with values increasing significantly at 60 and 90 min (P =
0.003 for time effect). Plasma CRP, MDA and several
FMD responses Figure 2
FMD responses. Mean (upper panel) and individual 
responses (lower panel) for peak flow mediated dilation 
(FMD) after ingestion of whey peptide (NOP-47) or Placebo. 
Significant differences between NOP-47 and Placebo (*P < 
0.005, **P < 0.001).
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inflammatory markers were unaffected by chronic or
acute ingestion (Table 3).
Discussion
We tested the effects of a novel peptide derived from whey
on vascular endothelial function in healthy, young men
and women. Peripheral vascular function was assessed in
a conduit vessel using FMD of the brachial artery by high-
resolution ultrasound and in forearm resistance vessels
using venous occlusion plethysmography. We demon-
strated that 2 wk of supplementation had no effect on fast-
ing measures of vascular function, but acute ingestion of
NOP-47 significantly increased postprandial FMD at 30,
60 and 90 min post-ingestion and reactive hyperemia
forearm blood flow measured at 120 min post-ingestion.
Shear stress induced dilation of conduit vessels like the
brachial artery are principally regulated by the potent
vasodilator NO· [28], whereas dilation of resistance ves-
sels in response to reactive hyperemia is largely independ-
ent of NO· [21]. Therefore acute ingestion of NOP-47
likely enhanced vascular endothelial function through
mechanisms that were dependent as well as independent
of NO·.
To define the NOP-47 mediated activity on vasodilation,
we measured NO· status by evaluating total nitrite and
nitrate levels (NOx), the final metabolites of NO·. We
detected a time-dependent decrease in plasma NOx during
the 2 h testing period that was partly inhibited after inges-
tion of NOP-47 at 120 min (Figure 4). Previous studies
have shown a decline in postprandial NOx and decreased
FMD after both high fat and high carbohydrate meals[29].
Lower NOx levels correlate with reduced FMD in patients
with endothelial dysfunction [30] and in healthy young
men and women [31]. Whether better maintenance of
NO· after NOP-47 ingestion contributed to the enhanced
vascular responses in this study remains unclear.
Although NOx correlates with FMD, the assay is not spe-
cific for endothelial NO· production and could also
reflect NO· derived from neuronal and inducible NO·
synthase [32]. Alternatively, other factors besides NO·
may be responsible for the enhanced dilation. Alterations
in the balance between vasodilators (e.g., bradykinin, ade-
nosine, vascular endothelial growth factor, and prostacyc-
lin) and vasoconstrictors (e.g., endothelin, prostanoids,
and angiotensin II) have been suggested to contribute to
the FMD response [33]. Experiments that involve infusion
of NG-nitro-L-arginine methyl ester (L-NAME), an inhibi-
tor of NO synthesis, would help to elucidate whether the
enhanced FMD response to NOP-47 is NO·-dependent.
Whey derived peptides showing ACE inhibitory effects are
released during normal digestion in the gastrointestinal
tract by proteases. Commonly used enzymatic procedures
in the manufacturing of whey hydrolysates also result in
rich sources of ACE inhibitory peptides. In order for oral
ingestion of whey peptides to exert hypotensive or other
biological effects in vivo, it must be absorbed intact and be
transported to the target tissue while escaping destruction
from intestinal brush border or serum peptidases. Evi-
dence exists to support that peptides are absorbed intact
Forearm blood flow responses Figure 3
Forearm blood flow responses. Reactive hyperemia fore-
arm blood flow was assessed using venous occlusion plethys-
mography 120 min after ingestion of whey peptide (NOP-47) 
Placebo. At each time point, reactive hyperemia induced 
forearm blood flow was assessed after 5 min of upper arm 
occlusion. Recovery of reactive hyperemic blood flow was 
determined after blocking the venous efflux of the upper arm 
for 7 sec during each of 8 subsequent 15-second cycles. Sig-
nificant differences between NOP-47 and Placebo (*P < 
0.05).
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Plasma total nitrites/nitrates (NOx), normalized to baseline,  responses to ingestion of a whey peptide (NOP-47) or Pla- cebo Figure 4
Plasma total nitrites/nitrates (NOx), normalized to 
baseline, responses to ingestion of a whey peptide 
(NOP-47) or Placebo. There was a significant main time 
effect. Significant differences between NOP-47 and Placebo 
(*P < 0.05).
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Table 3: Glycemic, oxidative stress, and inflammatory responses to whey peptide (NOP-47) and placebo.
Variables NOP-47 Placebo
Serum Glucose (mg/dL)
Pre (Pre-Supplementation) 93.2 ± 6.5 96.6 ± 9.0
Pre-Ingestion (2 wk Post) 93.9 ± 7.6 93.6 ± 7.0
15 min 93.7 ± 7.6 92.8 ± 6.0
30 min 94.1 ± 7.11 92.5 ± 6.1
45 min 93.5 ± 6.7 92.3 ± 5.8
60 min 93.0 ± 6.5 92.6 ± 7.0
90 min 93.7 ± 6.4 92.7 ± 6.6
120 min 93.4 ± 6.9 91.2 ± 6.5
Serum FRAP (μmol/L of Trolox Equivalents)
Pre (Pre-Supplementation) 364 ± 93 385 ± 78
Pre-Ingestion (2 wk Post) 354 ± 82 347 ± 67
15 min 370 ± 82 359 ± 76
30 min* 375 ± 80 369 ± 86
45 min 351 ± 78 366 ± 86
60 min 364 ± 76 358 ± 72
90 min 341 ± 73 359 ± 79
120 min 349 ± 76 349 ± 69
Plasma MPO (pmol/L)
Pre (Pre-Supplementation) 397 ± 162 362 ± 116
Pre-Ingestion (2 wk Post) 374 ± 117 347 ± 123
15 min 372 ± 118 361 ± 136
30 min 382 ± 145 358 ± 126
45 min 400 ± 132 366 ± 124
60 min* 431 ± 136 390 ± 133
90 min* 420 ± 125 394 ± 112
120 min 392 ± 135 377 ± 115
Plasma CRP (mg/dL)
Pre (Pre-Supplementation) 1.05 ± 0.88 1.75 ± 3.14
Pre-Ingestion (2 wk Post) 1.24 ± 1.51 1.11 ± 1.42
15 min 1.33 ± 1.73 1.01 ± 1.23
30 min 1.33 ± 1.77 1.14 ± 1.59
45 min 1.29 ± 1.75 1.15 ± 1.61
60 min 1.31 ± 1.77 1.08 ± 1.45
90 min 1.31 ± 1.75 1.09 ± 1.46
120 min 1.24 ± 1.65 1.02 ± 1.43
Plasma MDA (μmol/L)
Pre (Pre-Supplementation) 0.31 ± 0.13 0.37 ± 0.16
Pre-Ingestion (2 wk Post) 0.32 ± 0.13 0.31 ± 0.13
15 min 0.31 ± 0.13 0.30 ± 0.12
30 min 0.33 ± 0.13 0.30 ± 0.11
45 min 0.34 ± 0.14 0.31 ± 0.12
60 min 0.32 ± 0.12 0.30 ± 0.14
90 min 0.32 ± 0.15 0.30 ± 0.15
120 min 0.32 ± 0.16 0.30 ± 0.14
sE-selectin (ng/mL)
Pre (Pre-Supplementation) 22.6 ± 7.4 20.7 ± 8.5
Pre-Ingestion (2 wk Post) 19.6 ± 7.3 19.2 ± 7.3
60 min 20.0 ± 8.5 19.0 ± 7.6
120 min 19.7 ± 8.7 20.4 ± 8.6
sICAM-1 (ng/mL)
Pre (Pre-Supplementation) 104 ± 17 95 ± 25
Pre-Ingestion (2 wk Post) 100 ± 21 97 ± 13
60 min 96 ± 16 94 ± 21
120 min 96 ± 16 97 ± 17
sVCAM-1 (ng/mL)
Pre (Pre-Supplementation) 756 ± 145 732 ± 125
Pre-Ingestion (2 wk Post) 712 ± 124 709 ± 143
60 min 701 ± 112 700 ± 144Nutrition Journal 2009, 8:34 http://www.nutritionj.com/content/8/1/34
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through the intestine by paracellular and transcellular
routes[34]. Indeed, a specific whey-derived heptapeptide
having ACE inhibitory activity was demonstrated to be
bioavailable [35].
A possible mechanism by which whey peptides might
improve endothelial function is through ACE inhibition.
Human clinical trials have shown improvement in
endothelial function in patients taking ACE inhibitors
(reviewed in [4]), which could be the result of pleiotropic
effects of ACE inhibitors on the vascular endothelium
[15]. A further mechanism by which whey peptides could
affect vascular function is by increasing arginine availabil-
ity, the rate limiting substrate for nitric oxide synthesis.
However, NOP-47 contained approximately 135 mg of
arginine, well below the doses previously demonstrated to
improve FMD [36].
Most nutraceutical interventions that reported favorably
effects on FMD were studied after the ingestion of meals
that induced oxidative and inflammatory stress to the
endothelium leading to vascular dysfunction[5]. In this
study, our primary objective was to examine the effects of
NOP-47 in the fasted state without the confounding
effects of other nutrients in healthy non-hypertensive
individuals with presumed normal endothelial function-
ing. There was however a significant increase of ~15% in
plasma MPO one hour after ingestion of both NOP-47
and placebo suggesting the protocol induced a small tran-
sient elevation in neutrophil activation and oxidative
stress. The ischemia caused by repeated forearm arterial
and venous occlusions performed during the vascular
function tests may have produced brief periods of turbu-
lent flow causing an increase in MPO[37,38]. The increase
in MPO at 60 and 90 min after ingestion of both NOP-47
and placebo coincided in time with the significant
decrease in NOx. Elevated MPO levels have been shown to
interfere with endothelial NO· action and are highly asso-
ciated with impaired FMD[39].
Conclusion
The results of this preliminary study suggests that in indi-
viduals with normal endothelial function, the acute inges-
tion of a peptide derived from whey improves both
conduit and resistance vascular responses. Ingestion of
NOP-47 enhanced vascular function in the context of
minimal changes in glucose and markers of oxidative
stress and inflammation. The peptide could be of value in
populations with vascular dysfunction or as a method to
attenuate the vascular dysfunction associated with the
postprandial period. Future experiments that explore the
impact of NOP-47 on postprandial vascular function dur-
120 min 710 ± 118 719 ± 186
IL-6 (pg/mL)
Pre (Pre-Supplementation) 493 ± 1162 473 ± 1077
Pre-Ingestion (2 wk Post) 417 ± 1002 492 ± 1238
60 min 563 ± 1441 504 ± 1266
120 min 579 ± 1536 483 ± 1133
IL-8 (pg/mL)
Pre (Pre-Supplementation) 158 ± 243 139 ± 213
Pre-Ingestion (2 wk Post) 105 ± 183 159 ± 288
60 min 155 ± 323 164 ± 300
120 min 187 ± 370 183 ± 331
MCP-1 (pg/mL)
Pre (Pre-Supplementation) 435 ± 306 305 ± 132
Pre-Ingestion (2 wk Post) 428 ± 282 427 ± 244
60 min 447 ± 322 423 ± 276
120 min 398 ± 286 427 ± 316
TNF-alpha (pg/mL)
Pre (Pre-Supplementation) 39 ± 70 43 ± 89
Pre-Ingestion (2 wk Post) 19 ± 35 41 ± 105
60 min 39 ± 93 47 ± 120
120 min 63 ± 193 54 ± 141
VEGF (pg/mL)
Pre (Pre-Supplementation) 1320 ± 1394 1189 ± 1328
Pre-Ingestion (2 wk Post) 994 ± 1080 1206 ± 1435
60 min 1096 ± 1278 1201 ± 1401
120 min 1206 ± 1406 1273 ± 1548
Values are mean ± SD. *Significant main time effect, P < 0.05 from Pre-Ingestion.
FRAP = ferric-reducing ability of plasma; MPO = myeloperoxidase; CRP = C-reactive protein; MDA = malondialdehyde; sICAM-1 = soluble 
intercellular adhesion molecule-1; sVAM-1 = soluble vascular adhesion molecule-1; IL-6 = interleukin-6; MCP-1 = monocyte chemotactic protein-1; 
TNF-alpha = tumor necrosis factor alpha; VEGF = Vascular endothelial growth factor.
Table 3: Glycemic, oxidative stress, and inflammatory responses to whey peptide (NOP-47) and placebo. (Continued)Nutrition Journal 2009, 8:34 http://www.nutritionj.com/content/8/1/34
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ing hyperglycemia or hypertriglyceridemia with resulting
oxidative and inflammatory stress or studies that specifi-
cally address the therapeutic potential in patients with
vascular dysfunction would be informative.
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